We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

50 hedge funds and large institutions have $3.18M invested in Relmada Therapeutics in 2025 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more capital invested

Capital invested by funds: $1.68M → $3.18M (+$1.5M)

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

14% more funds holding

Funds holding: 44 → 50 (+6)

4.64% less ownership

Funds ownership: 20.61% → 15.98% (-4.6%)

54% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 13

Holders
50
Holders Change
+6
Holders Change %
+13.64%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
6
Reduced
13
Closed
7
Calls
$15K
Puts
–
Net Calls
+$15K
Net Calls Change
-$5K

Top Buyers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
+$380K
2
Corient Private Wealth
Corient Private Wealth
Florida
+$106K
3
Marshall Wace
Marshall Wace
United Kingdom
+$79.3K
4
ACM
ADAR1 Capital Management
Texas
+$66.7K
5
AI
AdvisorShares Investments
Maryland
+$61.6K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$433K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$312K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$135K
4
PAI
Palo Alto Investors
California
-$134K
5
Two Sigma Investments
Two Sigma Investments
New York
-$38.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
WIA
26
Wealthedge Investment Advisors
New York
$16.8K – – –
Group One Trading
27
Group One Trading
Illinois
$15.8K -$1.2K -2,340 -8%
Two Sigma Advisers
28
Two Sigma Advisers
New York
$15.1K -$135K -262,900 -91%
RSWM
29
Robertson Stephens Wealth Management
California
$15K – – –
TIM
30
Tortoise Investment Management
New York
$13K – – –
WIA
31
World Investment Advisors
California
$13K – – –
PW
32
Pandora Wealth
Illinois
$12K – – –
GSC
33
Ground Swell Capital
South Carolina
$9.2K +$7.86K +15,320 New
Lido Advisors
34
Lido Advisors
California
$8.35K – – –
HF
35
HRT Financial
New York
$7K -$20.5K -39,881 -77%
BFC
36
Bedel Financial Consulting
Indiana
$6K – – –
TRCT
37
Tower Research Capital (TRC)
New York
$3.71K +$3.18K +6,189 New
JP Morgan Chase
38
JP Morgan Chase
New York
$3.06K +$2.54K +4,945 +3,130%
ACA
39
American Capital Advisory
Idaho
$1.17K -$1K -1,954 -50%
Simplex Trading
40
Simplex Trading
Illinois
$1K -$1.05K -2,055 -46%
Morgan Stanley
41
Morgan Stanley
New York
$512 -$675 -1,316 -61%
Raymond James Financial
42
Raymond James Financial
Florida
$352 +$301 +587 New
Bank of America
43
Bank of America
North Carolina
$194 -$6.87K -13,392 -98%
SS
44
SBI Securities
Japan
$61 – – –
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$52 +$8 +15 +21%
Osaic Holdings
46
Osaic Holdings
Arizona
$3 – – –
FRA
47
Front Row Advisors
California
$2 -$2 -3 -50%
Citigroup
48
Citigroup
New York
$1 – – –
Barclays
49
Barclays
United Kingdom
$1 +$1 +1 New
PAI
50
Palo Alto Investors
California
– -$134K -495,146 Closed
1
2
3

RLMD Hedge Fund Activity: Q2 2025 in Review

50 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q2 2025, worth a combined $3.18M — up 89% from $1.68M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new RLMD positions and 7 closed out — a net gain of 6 holders — while 6 added to existing stakes and 13 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $380K. The largest seller was Vanguard Group, cutting an estimated $433K.

  • 50 institutional investors held Relmada Therapeutics (RLMD) as of Q2 2025, up from 44 in Q1 2025.
  • Funds reported $3.18M of Relmada Therapeutics stock for Q2 2025, up 89% quarter-over-quarter.
  • 13 funds opened new Relmada Therapeutics positions in Q2 2025 and 7 closed out, a net change of +6 holders.
  • The largest Relmada Therapeutics buyer in Q2 2025 was Driehaus Capital Management, an estimated $380K added.
  • The largest Relmada Therapeutics seller in Q2 2025 was Vanguard Group, an estimated $433K sold.

Based on aggregated 13F filings for Q2 2025.